National Hospital Organization Nagara Medical Center

Atamyo Therapeutics Announces First Patient Dosed with ATA-100 Gene Therapy in LGMD-R9 Clinical Trial

Retrieved on: 
Monday, September 26, 2022

John Vissing, Director of the Copenhagen Neuromuscular Center at the National Hospital, Rigshospitalet, in Copenhagen, where the first patient was dosed, and principal investigator of this trial.

Key Points: 
  • John Vissing, Director of the Copenhagen Neuromuscular Center at the National Hospital, Rigshospitalet, in Copenhagen, where the first patient was dosed, and principal investigator of this trial.
  • Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases.
  • A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon.
  • Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.

The First 1,000 Days: A Window of Opportunity for a Brighter Future for Children

Retrieved on: 
Friday, September 23, 2022

WASHINGTON, Sept. 23, 2022 /PRNewswire/ -- The infant and maternal mortality rates in the US are among the highest of any wealthy country, with glaring racial and ethnic disparities. There is significant room to develop a unifying plan for the right policies and systems to improve nutritional security and well-being for vulnerable families. As part of a special series, sponsored by 1,000 Days of FHI Solutions, that will appear in American Journal of Public Health (AJPH) on October 26, 2022. The full series will present the state of science, research needs, and a policy agenda for optimal maternal and child nutrition in the US.

Key Points: 
  • There is significant room to develop a unifying plan for the right policies and systems to improve nutritional security and well-being for vulnerable families.
  • As part of a special series, sponsored by 1,000 Days of FHI Solutions, that will appear in American Journal of Public Health (AJPH) on October 26, 2022.
  • The full series will present the state of science, research needs, and a policy agenda for optimal maternal and child nutrition in the US.
  • Thus, this journal series brings together papers on these topics during pregnancy, birth, the postpartum period, and early childhood for the US population.

Atamyo Therapeutics Obtains First Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-100, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2I/R9

Retrieved on: 
Monday, December 6, 2021

Atamyo plans to initiate dosing in patients for ATA-100 in the first half of 2022.

Key Points: 
  • Atamyo plans to initiate dosing in patients for ATA-100 in the first half of 2022.
  • ATA-100, a gene therapy candidate for LGMD21/R9, delivers a normal copy of the gene for production of FKRP proteins.
  • Atamyo Therapeutics is focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases.
  • A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon.